Brokerages forecast that Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Get Rating) will post $1.42 earnings per share (EPS) for the current fiscal quarter, according to Zacks. Five analysts have issued estimates for Collegium Pharmaceutical’s earnings, with estimates ranging from $1.25 to $1.75. Collegium Pharmaceutical reported earnings of $0.27 per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 425.9%. The business is scheduled to issue its next quarterly earnings results on Monday, January 1st.
On average, analysts expect that Collegium Pharmaceutical will report full year earnings of $5.55 per share for the current financial year, with EPS estimates ranging from $4.81 to $6.48. For the next year, analysts expect that the company will report earnings of $6.74 per share, with EPS estimates ranging from $5.29 to $8.48. Zacks Investment Research’s EPS averages are an average based on a survey of research firms that follow Collegium Pharmaceutical.
Collegium Pharmaceutical (NASDAQ:COLL – Get Rating) last announced its quarterly earnings results on Tuesday, May 10th. The specialty pharmaceutical company reported $0.44 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.90 by ($0.46). Collegium Pharmaceutical had a net margin of 15.68% and a return on equity of 3.26%. The business had revenue of $83.80 million during the quarter, compared to analysts’ expectations of $78.67 million. During the same period last year, the company earned $0.41 EPS. The firm’s revenue for the quarter was down 4.4% on a year-over-year basis.
A number of hedge funds have recently modified their holdings of the stock. Royal Bank of Canada increased its position in shares of Collegium Pharmaceutical by 126.3% in the first quarter. Royal Bank of Canada now owns 14,701 shares of the specialty pharmaceutical company’s stock worth $299,000 after acquiring an additional 8,206 shares in the last quarter. PDT Partners LLC acquired a new stake in shares of Collegium Pharmaceutical in the first quarter worth $301,000. Captrust Financial Advisors increased its position in shares of Collegium Pharmaceutical by 97.5% in the first quarter. Captrust Financial Advisors now owns 2,151 shares of the specialty pharmaceutical company’s stock worth $44,000 after acquiring an additional 1,062 shares in the last quarter. State Street Corp increased its position in shares of Collegium Pharmaceutical by 14.4% in the first quarter. State Street Corp now owns 1,308,167 shares of the specialty pharmaceutical company’s stock worth $26,634,000 after acquiring an additional 165,144 shares in the last quarter. Finally, Invesco Ltd. increased its position in shares of Collegium Pharmaceutical by 1.1% in the first quarter. Invesco Ltd. now owns 1,010,612 shares of the specialty pharmaceutical company’s stock worth $20,576,000 after acquiring an additional 11,090 shares in the last quarter.
Shares of NASDAQ COLL traded up $0.38 on Friday, hitting $16.36. The company’s stock had a trading volume of 207,851 shares, compared to its average volume of 399,810. Collegium Pharmaceutical has a 12-month low of $14.04 and a 12-month high of $25.66. The company has a market capitalization of $554.93 million, a price-to-earnings ratio of 18.38, a price-to-earnings-growth ratio of 0.16 and a beta of 1.07. The company has a debt-to-equity ratio of 3.41, a current ratio of 0.97 and a quick ratio of 0.76. The stock has a 50 day moving average of $17.85 and a 200-day moving average of $18.49.
About Collegium Pharmaceutical (Get Rating)
Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment.
- Get a free copy of the StockNews.com research report on Collegium Pharmaceutical (COLL)
- MarketBeat: Week in Review 5/16 – 5/20
- 3 Retailers That Defied First Quarter Headwinds
- Rapid7: Could Be Profitable in FY 2022 Despite Bear Market
- Will John Deere’s Earnings Help to Calm the Markets?
- Lowe’s Companies Has Not Bottomed
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.